1. Clinical & Scientific Overview
Fulvestrant (TIP-MED-000567, Reference Code [ONC-18]) is classified under
Oncology & Antineoplastic Medicines as a Hormonal Oncology Therapy (Pure ER Antagonist/Degrader) • Selective Estrogen Receptor Degrader (SERD).
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Faslodex (AstraZeneca Pharma India), Fulvenat (Natco Pharma), Strant (Dr. Reddy's Laboratories)
Pre-Filled Syringe for Intramuscular Injection: 250 mg/5 mL (2 syringes = 500 mg dose)
Oncology Specialisation & Cytotoxic Safety Protocol
Hormonal Oncology Therapy (Pure ER Antagonist/Degrader)
Antineoplastic Hormonal Agent
Standard Regimen & Cycle Context: 500 mg IM (administered as two slow 5 mL gluteal injections, one in each buttock) on Days 1, 15, and 29, and once monthly thereafter.
Signature Dose-Limiting Toxicities & Organ Monitoring: Injection-site pain and sciatica/peripheral neuropathy if injected improperly near the sciatic nerve; hot flushes, hepatic transaminase elevation, and cross-reactivity with immunoassays for serum estradiol (falsely elevates lab estradiol readings).
Extravasation, Premedication & Safe Cytotoxic Handling: Administer strictly as two slow (1–2 minutes per syringe) deep Z-track intramuscular injections into the dorsogluteal / ventrogluteal area (one 250 mg/5 mL syringe per buttock); store refrigerated at 2–8°C.
3. Mechanism of Action & Pharmacodynamics
7-alpha-alkylsulfinyl estradiol analogue that competitively binds estrogen receptors (ER) with 100x higher affinity than tamoxifen, blocks receptor dimerisation, and induces rapid proteasomal degradation of the ER protein without any agonistic activity on the endometrium.
4. Therapeutic Indications & Evidence-Supported Uses
- HR-positive, HER2-negative locally advanced or metastatic Breast Cancer (monotherapy or combined with CDK4/6 inhibitors Palbociclib/Ribociclib/Abemaciclib)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 500 mg IM (administered as two slow 5 mL gluteal injections, one in each buttock) on Days 1, 15, and 29, and once monthly thereafter.
Administration & Meal Timing: 500 mg IM (administered as two slow 5 mL gluteal injections, one in each buttock) on Days 1, 15, and 29, and once monthly thereafter.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Fulvestrant or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Injection-site pain and sciatica/peripheral neuropathy if injected improperly near the sciatic nerve; hot flushes, hepatic transaminase elevation, and cross-reactivity with immunoassays for serum estradiol (falsely elevates lab estradiol readings).
8. Adverse Effects Profile
- Injection-site pain and sciatica/peripheral neuropathy if injected improperly near the sciatic nerve; hot flushes, hepatic transaminase elevation, and cross-reactivity with immunoassays for serum estradiol (falsely elevates lab estradiol readings).
- Injection-site pain and sciatica/peripheral neuropathy if injected improperly near the sciatic nerve; hot flushes, hepatic transaminase elevation, and cross-reactivity with immunoassays for serum estradiol (falsely elevates lab estradiol readings).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Injection-site pain and sciatica/peripheral neuropathy if injected improperly near the sciatic nerve; hot flushes, hepatic transaminase elevation, and cross-reactivity with immunoassays for serum estradiol (falsely elevates lab estradiol readings).
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Administer strictly as two slow (1–2 minutes per syringe) deep Z-track intramuscular injections into the dorsogluteal / ventrogluteal area (one 250 mg/5 mL syringe per buttock); store refrigerated at 2–8°C.
Pharmacist Patient Counselling Points:
- Administer strictly as two slow (1–2 minutes per syringe) deep Z-track intramuscular injections into the dorsogluteal / ventrogluteal area (one 250 mg/5 mL syringe per buttock); store refrigerated at 2–8°C.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Administer strictly as two slow (1–2 minutes per syringe) deep Z-track intramuscular injections into the dorsogluteal / ventrogluteal area (one 250 mg/5 mL syringe per buttock); store refrigerated at 2–8°C.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-17] Anastrozole — Hormonal Oncology Therapy (Aromatase Inhibitor) • Third-Generatio
- [ONC-19] Enzalutamide — Hormonal Oncology Therapy (Antiandrogen) • Second-Generation Non-
- [ONC-20] Abiraterone Acetate — Hormonal Oncology Therapy (Androgen Biosynthesis Inhibitor) • Sel
- [ONC-21] Osimertinib Mesylate — Targeted Therapy (EGFR TKI) • Third-Generation Mutant-Selective I
